Search
for
Sort by
Research 30 of 1000+
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
- A hairy kinase
- OXI1 kinase is necessary for oxidative burst-mediated signalling in Arabidopsis
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- The Auxin-Regulated CrRLK1L Kinase ERULUS Controls Cell Wall Composition during Root Hair Tip Growth
- Protein Kinase C as a Therapeutic Target
- Protein Kinase Cε, which Sensitizes Skin to Sun's UV Radiation–Induced Cutaneous Damage and Development of Squamous Cell Carcinomas, Associates with Stat3
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- 2,3,7,8‐Tetrachlorodibenzo‐<i>p</i>‐dioxin causes an increase in protein kinases growth hepatic associated with epidermal factor receptor in the plasma membrane
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Inhibiting Janus kinases to treat alopecia areata
- Ornithine Decarboxylase Expression Leads to Translocation and Activation of Protein Kinase CK2 in Vivo
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Protein Kinase C δ Overexpressing Transgenic Mice Are Resistant to Chemically but not to UV Radiation–Induced Development of Squamous Cell Carcinomas: A Possible Link to Specific Cytokines and Cyclooxygenase-2
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Expression Profiles of Tyrosine Kinases in Cultured Follicular Papilla Cells Versus Dermal Fibroblasts
- Bisindolylmaleimide Protein-Kinase-C Inhibitors Delay the Decline in DNA Synthesis in Mouse Hair Follicle Organ Cultures
- Pyruvate Kinase M2 Accelerates Cutaneous Wound Healing via Glycolysis and Wnt/β-Catenin Signaling
- Protein Kinase C<i>ε</i>, Which Is Linked to Ultraviolet Radiation-Induced Development of Squamous Cell Carcinomas, Stimulates Rapid Turnover of Adult Hair Follicle Stem Cells
- Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Protein Kinase C Epsilon Signals Ultraviolet Light‐induced Cutaneous Damage and Development of Squamous Cell Carcinoma Possibly Through Induction of Specific Cytokines in a Paracrine Mechanism<sup>¶</sup>
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials